







SUPPLEMENT ARTICLE

Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy

Federica Novazzi¹  | Irene Cassaniti¹  | Antonio Piralla¹  |
Antonio Di Sabatino²  | Raffaele Bruno^{3,4}  | Fausto Baldanti^{1,4}  |
for the San Matteo Pavia COVID-19 Task Force*

¹Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

²Department of Internal Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

³Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

⁴Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy

Correspondence

Fausto Baldanti, Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Molecular Virology Unit, Microbiology and Virology Department, IRCCS Policlinico San Matteo, 27100 Pavia, Italy.

Email: fausto.baldanti@unipv.it; f.baldanti@smatteo.pv.it

Funding information

Ricerca Finalizzata, Grant/Award Number: GR-2013-02358399; Ricerca Corrente Fondazione IRCCS Policlinico San Matteo, Grant/Award Number: grant n. 80206

Editor: Gian Luigi Marseglia

Abstract

Coronavirus disease 2019 (COVID-19) diagnosis is based on molecular detection of SARS-CoV-2 in respiratory samples such as nasal swab (NS). However, the evidence that NS in patients with pneumonia was sometimes negative raises the attention to collect other clinical specimens. SARS-CoV-2 was shown in 10.3% rectal swabs (RS), 7.7% plasma, 1% urine, and 0% feces from 143 NS-positive patients. Potential infection by fluids different from respiratory secretion is possible but unlikely.

KEYWORDS

Coronavirus, COVID-19, epidemiology, northern Italy, SARS-CoV-2, specimen types, swabs, transmission routes

1 | INTRODUCTION

By December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started a new pandemic respiratory disease named 2019 novel coronavirus infectious disease (COVID-19).^{1,2} Lombardy Region (northern Italy) has been involved in a dramatic

COVID-19 epidemic episode since February 20 with a rapid increase in the rate of infected patients. At the time of writing, the number of infected people in Italy was higher than 97,000 with more than 40% of cases reported in the Lombardy Region.²

To date, the diagnosis of COVID-19 is based on the detection of SARS-CoV-2 RNA in respiratory samples such as nasal swab (NS).³

Novazzi and Cassaniti contributed equally.

San Matteo Pavia COVID-19 Task Force details present in Appendix 1.

© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

However, the evidence that NS in patients with COVID-19 pneumonia was sometimes negative raises the attention to collect other clinical specimens that may be useful for etiologic diagnosis since bronchoalveolar lavage (BAL) collection is not always possible.⁴ In the present study, we examined the presence of SARS-CoV-2 RNA in multiple biologic specimens collected simultaneously to respiratory samples from COVID-19 patients in order to determine the detection rate of viral RNA and the possibility of transmission by alternative routes.⁵

Overall, 143 patients with a confirmed diagnosis of COVID-19 by RT-PCR in respiratory samples and admitted to Infectious Diseases Department or at the Intensive Care Unit at Fondazione IRCCS Policlinico San Matteo were included in the study. In detail, 104/143 (72.7%) were males, and the mean age was 66.2 years (range, 2-94 years). Of them, 143 NS, 107 rectal swabs (RS), 85 urine, 26 plasma, and 5 feces were examined. We examined 18 urine and 39 RS samples from 59 patients with negative NS admitted to the emergency room department with respiratory distress.

Total nucleic acids (DNA/RNA) were extracted from 400 µL of samples using the QIAAsymphony® instrument with QIAAsymphony® DSP Virus/Pathogen Midi Kit (Complex 400 protocol) according to the manufacturer's instructions (QIAGEN, Qiagen). Specific real-time RT-PCR targeting RNA-dependent RNA polymerase and E genes were used to detect the presence of SARS-CoV-2 according to the WHO guidelines¹ and Corman et al protocols.³

Median and range were given for quantitative variables, while qualitative variables were shown as percentages or frequencies.

A total of 366 specimens corresponding to 143 consecutive patients were examined. In detail, 11/107 (10.3%) patients had a COVID-19-positive RS, 2/26 (7.7%) patients had a COVID-19-positive plasma, while only 1/85 (1.2%) had a COVID-19-positive urine sample. None of the 5 stool specimens tested positive.

The median viral load detected in respiratory samples was 4×10^6 copies/ml (range 1.7-6.9), while it was 4.1×10^6 copies/ml (range 1.7-6.5) in RS and 2.9×10^6 copies/ml (range 2.9-3) in two positive plasma (Table 1). The most common clinical features of hospitalized patients with COVID-19 were fever, dry cough, dyspnea, diarrhea, asthenia, and respiratory disorders as pneumonia and sore throat.

None of the 116 specimens (59 NS, 18 urine, and 39 RS), from 59 COVID-19-negative control patients, tested positive.

Key Message

The present study aims to define the possibility of SARS-CoV-2 transmission by alternative routes.

The transmission of SARS-CoV-2 through direct contact with infected secretion or aerosol droplets is well known.⁵ However, in the past epidemics caused by other coronaviruses (SARS-CoV-1 and MERS-CoV), viral RNA was also detected in several clinical specimens such as 42% urine, 97% stool, and 50% plasma.⁶⁻⁸ In this respect, these materials have been considered as useful clinical samples to improve laboratory diagnosis.

Also, the possibility of different SARS-CoV-2 transmission routes could be contemplated. In this brief report, we described the presence of the virus in different clinical samples, including RS, plasma, and urine, supporting the evidence of a potential shed of the virus through fecal-oral or body fluid routes.

In this study, the highest rate of positive RT-PCR for SARS-CoV-2 was detected in RS specimens (10.3%), suggesting that SARS-CoV-2 may be transmitted by the fecal route.⁵ However, this rate is lower than SARS-CoV-1.

Focusing on plasma samples, we reported only a few cases of positive RNA detection in plasma (7.7%), but higher than that reported by Wang et al,⁵ suggesting a systemic infection can occur although less frequently with respect to 50% SARS-CoV-1.⁹

The SARS-CoV-2 was rarely detected in urine, and to date, no other authors reported a significant presence of the virus in urine of COVID-19 patients.

Although SARS-CoV-2 was detected in specimens from multiple sites of patients with positive NS for COVID-19, no positive results were obtained in patients with negative NS, supporting the hypothesis that respiratory samples represent the gold standard for COVID-19 molecular diagnosis.

Transmission of SARS-CoV-2 by respiratory droplets and other way routes highlights the risk of contagious via environmental contamination with infected clinical specimens, highlighting the importance of protection and decontamination procedures despite extensive contamination of inanimate surfaces.¹⁰ Longitudinal studies should be performed to evaluate the

TABLE 1 RNA load test results of the 143 hospitalized patients SARS-CoV-2-positive by real-time RT-PCR

	NS (143)	RS (107)	URINE (85)	PLASMA (26)	FECES (5)
Positive test results no (%)	143 (100%)	11 (10.3%)	1 (1.2%)	2 (7.7%)	0
RNA load (log10)/ml, median	4 (3.9)	4.1 (1.8)	5.0*	2.9 - 3*	ND
Range	1.7-6.9	1.7-6.5	ND	ND	ND
95% CI	28.8-30.4	2.9-5.3	ND	ND	ND

Abbreviation: NS, nasal swab; RS, rectal swab; ND, no data.

*Median was not available for one/two positive value.

incidence of SARS-CoV-2 RNA in specimens different from respiratory samples.

ACKNOWLEDGMENTS

This work was supported by funds from the Italian Ministry of Health (Finalised Research/Ricerca Finalizzata grant no. GR-2013-02358399) and Ricerca Corrente Fondazione IRCCS Policlinico San Matteo (grant no. 80206). We thank Daniela Sartori for manuscript editing.

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

ORCID

Federica Novazzi  <https://orcid.org/0000-0002-2741-8840>
 Irene Cassaniti  <https://orcid.org/0000-0002-3385-2088>
 Antonio Piralla  <https://orcid.org/0000-0002-6062-2579>
 Antonio Di Sabatino  <https://orcid.org/0000-0002-0302-8645>
 Raffaele Bruno  <https://orcid.org/0000-0002-0235-9207>
 Fausto Baldanti  <https://orcid.org/0000-0002-3358-8969>

REFERENCES

1. WHO. Novel coronavirus – China. <http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/>. Accessed Jan 19, 2020. Jan 12, 2020
2. Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. *JAMA*. 2020;323:1335.
3. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25:2000045.
4. Winichakoon P, Chaiwarith R, Liwsrisakun C, et al. Negative nasopharyngeal and oropharyngeal swab does not rule out COVID-19. *J Clin Microbiol*. 2020;58:e00297-20.
5. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA*. 2020;323:1843-1844.
6. Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *J Pathol*. 2004;203:622-630.
7. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. *Sci Adv*. 2017;3:eaa04966.
8. Niedrig M, Patel P, El Wahed AA, Schädler R, Yactayo S. Find the right sample: A study on the versatility of saliva and urine samples for the diagnosis of emerging viruses. *BMC Infect Dis*. 2018;18:707.
9. Wang WK, Fang CT, Chen HL, et al. Detection of severe acute respiratory syndrome coronavirus RNA in plasma during the course of infection. *J Clin Microbiol*. 2005;43:962-965.
10. Colaneri M, Seminari E, Piralla A, et al. Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. *J Hosp Infect*. 2020;105:474-476.

How to cite this article: Novazzi F, Cassaniti I, Piralla A, Di Sabatino A, Bruno R, Baldanti F; for the San Matteo Pavia COVID-19 Task Force. Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. *Pediatr Allergy Immunol* 2020;31(Suppl. 26):72-74. <https://doi.org/10.1111/pai.13366>

APPENDIX 1.

The San Matteo Pavia COVID-19 Task Force consisted of: R Bruno, M Mondelli, E Brunetti, A Di Matteo, E Seminari, L Maiocchi, V Zuccaro, L Pagnucco, B Mariani, S Ludovisi, R Lissandrini, A Parisi, P Sacchi, SFA Patruno, G Michelone, R Gulminetti, D Zanaboni, S Novati, R Maserati, P Orsolini, M Vecchia (Infectious Disease Staff); M Sciarra, E Asperges, M Colaneri, A Di Filippo, M Sambo, S Biscarini, M Lupi, S Roda, TC Pieri, I Gallazzi, M Sachs, P Valsecchi (Infectious Disease Resident); S Perlini, C Alfano, M Bonzano, F Briganti, G Crescenzi, AG Falchi, R Guarnone, B Guglielmana, E Maggi, I Martino, P Pettenazza, S Pioli di Marco, F Quaglia, A Sabena, F Salinaro, F Speciale, I Zunino (ICU Staff Emergency Care Unit); M De Lorenzo, G Secco, L Dimitry, G Cappa, I Maisak, B Chiodi, M Sciarrini, B Barcella, F Resta, L Moroni, G Vezzoni, L Scattaglia, E Boscolo, C Zattera, MF Tassi, V Capozza, D Vignaroli, M Bazzini (ICU Resident Emergency Care Unit); G Iotti, F Mojoli, M Belliato, L Perotti, S Mongodi, G Tavazzi (Intensive Care Unit); G Marseglia, A Licari, I Brambilla (Pediatric Unit); D Barbarini, A Bruno, P Cambieri, G Campanini, C Cavanna, G Comolli, M Corbella, R Daturi, M Furione, B Mariani, P Marone, R Maserati, E Monzillo, S Paolucci, M Parea, E Percivalle, A Piralla, F Rovida, A Sarasini, M Zavattoni (Virology Staff); G Adzasehoun, M Ardizzone, L Bellotti, V Brunco, E Cabano, G Casali, L Capella, D Devitis, L Dossena, G Frisco, G Garbagnoli, F Gardellini, A Girello, A Guerrizio, V Landini, C Lucchelli, V Maliardi, P Piemontese, S Pezzaia, M Premoli, C Rebuffa, C Zanello (Virology Technical staff); J Bagnarino, F Bergami, A Bonetti, G Caneva, I Cassaniti, A Corcione, R Di Martino, A Di Napoli, A Ferrari, G Ferrari, L Fiorina, A Gallone, F Giardina, A Girardi, A Mercato, F Novazzi, G Ratano, B Rossi, G Saveriaempillai, IM Sciabica, M Tallarita, E Vecchio Nepita, J Vitali (Virology Resident); A Cerino, S Varchetta, B Oliviero, S Mantovani, D Mele (Research Laboratories, Division of Infectious Diseases and Immunology); M Calvi, M Tizzoni (Pharmacy Unit); C Nicora, A Triarico, V Petronella, C Marena, A Muzzi, P Lago, S Cutti, V Novelli (Hospital Management); F Comandatore, G Batisti Biffignandi, S Gaiarsa, M Rettani, C Bandi, A Ferrari (Data Unit).